Cuprina Holdings Closes $4.97 Million Public Offering

SINGAPORE, Sept. 17, 2026 /CourierPR/ -- Cuprina Holdings (Cayman) Limited, a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, has successfully closed its public offering of 4,322,489 Class A Ordinary Shares at a price of $1.15 per share. The offering raised a total of approximately $4.97 million in gross proceeds, before deducting underwriting discounts and offering expenses.

The company has also granted the underwriter, R. F. Lafferty & Co., Inc., a 45-day option to purchase up to an additional 648,373 shares of its Class A Ordinary Shares at the Offering Price, representing 15% of the Class A Ordinary Shares sold in the Offering. If the over-allotment is exercised, the company is expected to receive gross proceeds amounting to approximately $5.72 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Cuprina Holdings intends to use the net proceeds from the Offering for expansion into new businesses, R&D activities to expand its product offerings, growth and expansion into new markets, building brand awareness, investment in equipment and infrastructure, and working capital and general corporate purposes. The company has previously received U.S. FDA 510(k) clearance for its MEDIFLY Maggots™ product in June.

"The Offering comes at an important stage for the Company, following U.S. FDA 510(k) clearance for MEDIFLY Maggots™ in June. We intend to use the net proceeds as described in our prospectus, including building out our new business collaborations, advancing our wound care pipeline, and expanding into new markets."

"Chronic wounds remain the core of our business. We believe demand for effective wound care will keep growing as populations age and rates of diabetes, obesity, cardiovascular disease, and peripheral vascular disease rise. We also believe our approach, which uses materials derived from natural sources, positions Cuprina to meet that need, and we look forward to updating shareholders on our progress," Quek added.

The Offering was conducted pursuant to the Company’s Registration Statement on Form F-1 (File No: 333-297299) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (SEC) on September 15, 2026. The Offering is being made only by means of a prospectus. Before investing, potential shareholders should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering.